On this basis and considering our previous results that delineated the role of SCD1 in: i) maintaining the CSC compartment in lung cancer [27], and ii) inducing chemotherapy-resistant features [28], we hypothesized that lipid metabolic reprogramming may be also a distinctive feature of melanoma CSCs, and that this phenomenon installs therapeutic resistance. The gene discussed is SCD; the disease is melanoma.